<DOC>
	<DOC>NCT02596958</DOC>
	<brief_summary>The purpose of this non-interventional study is the collection and documentation of data on safety and efficacy of intravenous (IV) bevacizumab (Avastin) in addition to platinum-based chemotherapy for first-line treatment in participants with unresectable advanced, metastatic or recurrent non-small cell lung cancer (NSCLC) other than predominantly squamous cell histology with focus on adenocarcinoma and elderly patients in daily routine.</brief_summary>
	<brief_title>Safety and Efficacy Study of Avastin in Locally Advanced Metastatic or Recurrent Non-small Lung Cancer (NSLC) Participants</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Age greater than or equal to (&gt;=) 18 years Histologically confirmed predominantly nonsquamous NSCLC that is unresectably advanced, metastatic or recurrent (with or without adenocarcinoma) No contraindications to Avastin® according to the current Summary of Product Characteristics (SmPC) for Avastin® Therapeutic decision for Avastin® as first line treatment in combination with platinumbased chemotherapy was taken individually and independent of the noninterventional trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>